Last Update 22 Jun 26
GENT: Pipeline Reallocation After Assay Exit Will Support Future Upside
Analysts have maintained their fair value estimate for Gentian Diagnostics at NOK 60.0, citing largely unchanged assumptions on growth, margins and future P/E that support a steady price target outlook.
What’s in the News for Gentian Diagnostics
- Gentian Diagnostics ASA has decided to discontinue development of its NT proBNP heart failure biomarker assay after a review of performance data and market conditions, citing limited commercial demand and high technical risk in a competitive market. Source: Company key developments
- The company has fully written off the NT proBNP project, with an impairment charge of NOK 30.2 million recognised in the Q1 2026 accounts, while stating that the charge does not affect its cash position. Source: Company key developments
- Resources from the discontinued NT proBNP program are being reallocated to other opportunities in Gentian Diagnostics ASA’s product pipeline, in line with its portfolio management priorities. Source: Company key developments
- Gentian Diagnostics ASA has called its annual general meeting for 5 May 2026, where the board is proposing a new authorisation to issue shares that could increase current share capital by up to 10%. Source: Company key developments
- The proposed share issuance authorisation would allow the board to amend the articles of association to reflect any capital increases, with the authorisation valid until the 2027 annual general meeting, but not later than 30 June 2027. Source: Company key developments
Valuation Changes
- Fair Value: NOK 60.0 remains unchanged, indicating a stable fair value assessment for Gentian Diagnostics.
- Discount Rate: Adjusted marginally from 7.03% to 7.03%, with the change too small to materially affect the valuation outcome.
- Revenue Growth: Kept at 16.77%, reflecting consistent assumptions for future NOK revenue expansion.
- Net Profit Margin: Held steady at 29.86%, indicating unchanged expectations for future profitability levels.
- Future P/E: Maintained effectively in line with prior assumptions at around 13.19x, with only a very small numerical adjustment.
Key Takeaways
- Expansion of PETIA technology and product portfolio is anticipated to drive substantial future revenue and earnings growth.
- Strategic contract acquisitions and market expansion for key products are expected to enhance revenues, margins, and overall profitability.
- Reliance on specific products and geopolitical factors, combined with increased costs and exchange rate risks, could challenge Gentian's financial stability and profitability.
Catalysts
About Gentian Diagnostics- Researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide.
- Gentian Diagnostics is targeting a large serviceable market of $1.8 billion in the diagnostic market with certain segments growing at a 5% to 10% pace, which can significantly impact future revenue growth.
- The company aims to leverage its focus on PETIA technology for high throughput analyzers and plans to expand its product portfolio, expected to drive future revenue.
- Gentian's strategic aim to secure on average one new contract with a global player per year is a forward-looking catalyst that can boost earnings and revenue.
- Their focus on growing established products, such as aiming for GCAL and NT-proBNP commercialization by expanding market presence, is set to contribute to higher future revenues and EBITDA growth.
- The company is actively improving gross margins, demonstrated by an increase to 56% from 43%, and targets long-term EBITDA margins of 40%, which suggests expected improvements in net margins and profitability.
Gentian Diagnostics Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Gentian Diagnostics's revenue will grow by 16.8% annually over the next 3 years.
- Analysts assume that profit margins will increase from -8.4% today to 29.9% in 3 years time.
- Analysts expect earnings to reach NOK 83.6 million (and earnings per share of NOK 3.12) by about June 2029, up from -NOK 14.8 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 13.6x on those 2029 earnings, up from -39.1x today. This future PE is lower than the current PE for the NO Medical Equipment industry at 26.1x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.03%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The company experienced a 30% revenue drop in Asia, specifically due to challenges in China related to a new value-based pricing tender system, which could negatively impact future revenues if not resolved.
- Despite strong growth in other regions, the company's financial performance is heavily reliant on specific products such as fCAL turbo, which may expose the company to risk if these products face increased competition or market saturation, potentially impacting future revenues.
- The company's long-term success in expanding markets like the U.S. could be hindered by potential geopolitical factors such as tariffs, which could impact Gentian's revenue and profitability.
- Gentian's R&D and administrative costs are expected to increase, particularly due to regulatory burdens, which may affect their net margins and overall profitability.
- The impact of exchange rate fluctuations remains a risk for Gentian, given that the majority of their revenue is in euros, U.S. dollars, and Chinese yuan while costs are primarily in NOK, affecting the company's earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of NOK60.0 for Gentian Diagnostics based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be NOK280.1 million, earnings will come to NOK83.6 million, and it would be trading on a PE ratio of 13.6x, assuming you use a discount rate of 7.0%.
- Given the current share price of NOK37.4, the analyst price target of NOK60.0 is 37.7% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Gentian Diagnostics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.